GPX4 and metabolic dysfunction-associated steatohepatitis: Remarkably, Qi et al. observed that RSL3 treatment can aggravate manifestations (levels of serum biochemical parameters, hepatic steatosis, and inflammation) of methionine/choline-deficient (MCD) diet-induced NASH mice, while administration of sodium selenite (a GPx4 activator), deferoxamine mesylate salt, or liproxstatin could rescue RSL3 induced lipid peroxidation and cell death as well as the NASH severity [54].